2021年最新SCI期刊影响因子查询系统
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 期刊详细信息
基本信息
期刊名称 | CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS |
---|---|
期刊ISSN | 1084-9785 |
期刊官方网站 | http://www.liebertpub.com/overview/cancer-biotherapy-and-radiopharmaceuticals/8/ |
是否OA | 否 |
出版商 | Mary Ann Liebert Inc. |
出版周期 | Bimonthly |
始发年份 | 1996 |
年文章数 | 57 |
最新影响因子 | 3.632(2021) |
中科院SCI期刊分区
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学4区 | MEDICINE, RESEARCH & EXPERIMENTAL 医学:研究与实验4区 | 否 | 否 |
ONCOLOGY 肿瘤学4区 | |||
PHARMACOLOGY & PHARMACY 药学4区 | |||
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学4区 |
CiteScore
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 1.70 | 0.545 | 0.609 |
Medicine Radiology Nuclear Medicine and imaging |
110 / 272 | 59% |
|||
Biochemistry, Genetics and Molecular Biology Cancer Research |
151 / 191 | 21% |
|||
Pharmacology, Toxicology and Pharmaceutics Pharmacology |
173 / 300 | 42% |
|||
Medicine Oncology |
205 / 321 | 36% |
补充信息
自引率 | 4.00% |
---|---|
H-index | 51 |
SCI收录状况 |
Science Citation Index
Science Citation Index Expanded |
官方审稿时间 | |
网友分享审稿时间 | 数据统计中,敬请期待。 |
PubMed Central (PML) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1084-9785%5BISSN%5D |
投稿指南
期刊投稿网址 | http://mc.manuscriptcentral.com/Cancerbiotherapy |
---|---|
收稿范围 | Cancer Biotherapy and Radiopharmaceuticals provides peer-reviewed research on cutting-edge therapeutic investigations and advancements in radioimmunotherapy for treating cancer. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Cancer Biotherapy and Radiopharmaceuticals coverage includes: Antibody drug conjugates Fusion toxins and immunotoxins Nanoparticle therapy Vascular therapy Inhibitors of proliferation signaling pathways Cancer Biotherapy and Radiopharmaceuticals is under the editorial leadership of Editor-in-Chief Martin W. Brechbiel, PhD and other leading investigators. Audience: Oncologists, nuclear medicine researchers, radiologists, cancer researchers, pathologists, and epidemiologists, among others. |
收录体裁 | |
投稿指南 | |
投稿模板 | |
参考文献格式 | |
编辑信息 |